Sarcopenia and Frailty as a Prognostic/Outcome Biomarker of Urological Cancer Patients

Dear Colleagues,

Sarcopenia is a condition characterized by the degenerative and systemic loss of skeletal muscle mass with the reduction of skeletal muscle strength and physical performance. Sarcopenia reflects not only the frailty of the host and intolerance to cancer therapy but also the presence of cancer cachexia. Thus, sarcopenia is one of the most clinically important factors in the management of cancer-bearing patients.

In the field of urological cancers, including urothelial cancer, kidney cancer, and prostate cancer, a growing number of studies have shown the strong prognostic value of sarcopenia in association with therapeutic modalities according to the disease extent. Currently, minimally invasive robotic surgery is becoming a mainstay of urological cancer surgery. Moreover, the clinical use of novel anti-cancer therapeutics such as immuno-oncology drugs and antibody–drug conjugates is rapidly expanding in urological cancers. With these paradigm shifts in cancer therapy, the prognostic significance of sarcopenia should be verified.

This Special Issue of Cancers focuses on the role of sarcopenia as a prognostic biomarker of urological cancer patients in contemporary clinical practice. This special issue also covers frailty as a treatment outcome biomarker of those patients.

Dr. Fumitaka Koga
Dr. Hiroshi Fukushima
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.